Migraine

Cluster Headache

Trigeminal Autonomic Cephalgia

Hemicrania Continua

Paroxysmal Hemicrania

SUNCT

Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing

Subjects will drink a solution with capsaicin

Oral capsaicin

Capsaicin cream will be applied to the skin of the forehead, cheek, or leg

Topical capsaicin

Capsaicin cream will be applied to the nostril

Intranasal capsaicin

Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)

Cold Water Irrigation

Medical Air

Subjects will be exposed to oxygen gas between 1-9 L/min

Low Flow Oxygen

Subjects will be exposed to oxygen gas between 10-25 L/min

High Flow Oxygen

The University of Texas Health Science Center at Houston

Pain Biomarker Study

The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors

The amount of tear fluid after each intervention will be measured via Schirmer strips

Mark J Burish

Assistant Professor

The University of Texas Health Science Center, Houston

University of California, San Francisco

In the oxygen portion of the study, subjects and the outcomes assessors will be told that they will be receiving either medical air or oxygen.

Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.

Secondary Headache Disorder

Restricted to female due to: a) higher prevalence of the condition in this group and b) small sample size

All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.
In addition, they will undergo 3 cycles of treatment, each 12 weeks apart.

Botulinum Toxin type A

University at Buffalo

The Effect of Botulinum Toxin A on Headache Attributed to TMD

The Effect of Botulinum Toxin A (BOTOX®) on Headache Attributed to TMD - An Open Label Trial

Using algometer at the temporalis and masseter muscles

This scale provides the characterization of chronic pain as well as disability associated to the chronic pain. This scale includes 3 items for pain intensity and 4 items for function, one item for number of days of pain.
Characteristic Pain Intensity (CPI): compute mean of items 2-4(pain right now, worst pain, average pain), and multiply by 10.
Interference Score: compute mean of items 6-8 (daily activities, social activities, work activities), and multiply by 10.
Interpretation Determination of Chronic Pain Grade Grade 0: (no pain, no disability)
I Low intensity pain, without disability: (Less than 50 points in CPI and less than 3 point in disability)
II: High Intensity pain, without disability: (Greater than or equal to 50 points in CPI and less than 3 point in disability
III: Moderately limiting: N/A in CPI and 3-4 points in disability
IV: Severely limiting: N/A in CPI and 5-6 points in disability

Comprised within a 20-item instrument. a single global score of "jaw functional limitation" can be computed as the mean of the available items. Sub-scale scores for each type of functional limitation are computed, as follows: Mastication: mean of items 1-6. Mobility: mean of items 7-10. Verbal and non-verbal communication: mean of items 13-20. Norms have not yet been established for this instrument.

This self reported instruments comprise 6 items and based on the number of days of disability a MIDAS level is calculated as follows:
0 to 5- MIDAS Grade I, Little or no disability 6 to 10- MIDAS Grade II, Mild disability 11 to 20- MIDAS Grade III, Moderate disability 21+ MIDAS Grade IV, Severe disability

State University of New York at Buffalo

This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.

This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.

Headache Disorders

Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.

Capsaicin

This group will receive the saline placebo solution.

Placebo

Capsaicin in Treatment of Rhinogenic Headache

The Role of Topical Capsaicin in Treatment of Rhinogenic Headache

We will track the amount of headache medication used during the study period

patients will be asked to report any adverse reactions or events during the study period.

Patient will be asked to record the number of headaches during the study period, and record the severity from 1-10 on the Visual Analog Scale (VAS)

Karli Davis

University of Nebraska

Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.

Fracture of Nasal Bones, Sequela

Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.

Cold dry air machine

Design of a Model to Study Functionality of the Trigeminal Nerve in Relation to Controlled Nasal Fractures

Short Cold Dry Air (CDA) provocation with symptom evaluation using VAS and PNIF post-provocation and collection of nasal fluid by Merocel after provocation.

The presence of nasal obstruction will be evaluated on a VAS scoring system (0-10 cm) on the baseline visit and on follow-up visits. All patients will be asked to mark their nasal obstruction on this VAS score on all visits before and after CDA and capsaicin provocation.

Collection of nasal fluid: nasal fluid will be collected, by placing a small Merocel (4 cm) between the middle and inferior turbinate, for 5 minutes. This technique is a traumatic and painless for the patient, and allows a rapid collection of nasal fluid without the need for local anesthesia. The fluid will be stored at -20°C until analysis, i.e. measurement of mediators such as histamine, Substance P (SP), Neurokinin A and B (NKA, NKB), Nerve Growth Factor (NGF), eotaxin, NPY, CGRP by ELISA. All these measurements will be aggregated to arrive at one reported value an increase of neuro mediators in the immediate postoperative period and gradual decrease to the baseline levels over a period of time.

The presence of rhinorrhea will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their nasal rhinorrhea on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of facial pain will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their facial pain on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of sneezing will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their sneezing on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of facial pain will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their facial pain on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of sneezing will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their sneezing on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of pruritus will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their pruritus on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of pruritus will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their pruritus on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of sneezing will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their sneezing on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of catarrh will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their catarrh on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of pruritus will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their pruritus on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of catarrh will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their catarrh on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of facial pain will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their facial pain on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of pruritus will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their pruritus on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of hyposmia will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their sense of smell on this VAS score on all visits before and after CDA and capsaicin provocation.

The presence of facial pain will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their facial pain on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of pruritus will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their pruritus on this VAS score on all visits before and after CDA and capsaicin provocation.
The presence of headache will be evaluated on a VAS scoring system (0-10 cm) on the baseline and follow-up visits. All patients will be asked to mark their headache on this VAS score on all visits before and after CDA and capsaicin provocation.

Garyafalia Lekakis

Research Associate

KU Leuven

This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.

Cheek swabs, on the right and left inner cheek. Others:Cerebrospinal fluid samples,Blood samples Urine samples.

Chronic Fatigue Syndrome

Fibromyalgia

Gulf War Illness

Multiple Chemical Sensitivity

Interstitial Cystitis

Irritable Bowel Syndrome

Georgetown University Hospital, 3800 Reservoir Rd NW

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

Identify Unique Set of Proteins in Cerebrospinal Fluid, Which Are Believed to be Found in Chronic Fatigue Syndrome Participants, But Not in Healthy Controls.

capsaicin/sakit kepala

Pain Biomarker Study

The Effect of Botulinum Toxin A on Headache Attributed to TMD

Capsaicin in Treatment of Rhinogenic Headache

Design of a Model to Study Functionality of the Trigeminal Nerve in Relation to Controlled Nasal Fractures

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

Database tanaman obat terlengkap yang didukung oleh sains